Anika Therapeutics, Inc.
ANIK
$15.03
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.60M | 38.75M | 41.92M | 40.52M | -2.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.60M | 38.75M | 41.92M | 40.52M | -2.90M |
| Cost of Revenue | 12.87M | 37.31M | 14.56M | 15.42M | -8.67M |
| Gross Profit | 17.73M | 1.44M | 27.37M | 25.10M | 5.77M |
| SG&A Expenses | 11.32M | 19.11M | 19.81M | 26.53M | -15.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.70M | 63.67M | 41.76M | 50.11M | -27.60M |
| Operating Income | -100.00K | -24.92M | 161.00K | -9.59M | 24.70M |
| Income Before Tax | 38.00K | -27.61M | 756.00K | -4.47M | 25.28M |
| Income Tax Expenses | 2.52M | 2.31M | 844.00K | 43.00K | 9.05M |
| Earnings from Continuing Operations | -2.49M | -29.92M | -88.00K | -4.51M | 16.23M |
| Earnings from Discontinued Operations | -19.38M | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.87M | -29.92M | -88.00K | -4.51M | -63.00M |
| EBIT | -100.00K | -24.92M | 161.00K | -9.59M | 24.70M |
| EBITDA | 2.09M | -22.73M | 2.22M | -7.53M | 28.28M |
| EPS Basic | -1.50 | -2.03 | -0.01 | -0.31 | -4.30 |
| Normalized Basic EPS | 0.03 | -1.04 | 0.03 | -0.38 | 1.08 |
| EPS Diluted | -1.50 | -2.03 | -0.01 | -0.31 | -4.30 |
| Normalized Diluted EPS | 0.03 | -1.04 | 0.03 | -0.38 | 1.08 |
| Average Basic Shares Outstanding | 14.58M | 14.77M | 14.84M | 14.70M | 14.66M |
| Average Diluted Shares Outstanding | 14.62M | 14.77M | 14.84M | 14.70M | 14.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
